Hanmi Toughens Controls As Employees Arrested For Insider Trading
Executive Summary
Prosecutors' two-month probe into Hanmi Pharmaceutical has concluded without a big bang after they found the South Korean firm did not intentionally delay the disclosure of a licensee decision to end a cancer drug partnership, but several employees have nevertheless been arrested over improper information leakage.
You may also be interested in...
Hanmi Halts Olmutinib Development After Alliances Crumble
Hanmi is set to focus on other assets in its innovative drug pipeline after it ends development of novel lung cancer drug olmutinib amid ZAI Lab’s recent cancellation of a licensing agreement with the South Korean pharma.
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.